18F-FluorThanatrace PET/CT Imaging for Prostate Cancer

Recruiting in Palo Alto (17 mi)

Overseen by Dan Pryma, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Abramson Cancer Center of the University of Pennsylvania

No Placebo Group

Trial Summary

What is the purpose of this trial?

Men with a history of prostate cancer may be in this study. Subjects recommended for a prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer \[18F\]FTT to evaluate PARP-1 activity in known or suspected sites of primary or metastatic disease. Imaging will be compared with pathology results, including additional research assays when possible.

Eligibility Criteria

Men over 18 with biopsy-proven prostate cancer, who have at least one tumor lesion of 1 cm or larger. They must be recommended for a prostatectomy or oligometastectomy and willing to provide tissue samples for research. Excluded are those unable to tolerate imaging, with serious health/psychological issues, or unable to give informed consent.

Inclusion Criteria

Participants must be willing to allow use or collection of pathology tissue for research purposes

Participants must be informed of the investigational nature of the study and provide written informed consent

I am 18 years old or older.

Exclusion Criteria

Inability to tolerate imaging procedures

Presence of serious or unstable medical or psychological conditions that would compromise safety or successful participation in the study

Individuals who are mentally disabled

Treatment Details

Interventions

• [18F]FluorThanatrace (Imaging)
• Poly(ADP Ribose) Polymerase 1 (Poly(ADP Ribose) Polymerase (PARP) Inhibitor)

Trial Overview The study tests a new PET/CT imaging method using [18F]FluorThanatrace (FTT) to measure PARP-1 activity in primary or metastatic prostate cancer sites. The results will be compared with pathology findings from surgeries like prostatectomies.

Participant Groups

Group I: Cohort 3 Experimental Treatment 2 Interventions

Gleason 9 or oligometastic disease (n=10)

Group II: Cohort 2 Experimental Treatment 2 Interventions

Gleason 7-8 (n=10)

Group III: Cohort 1 Experimental Treatment 2 Interventions

Gleason 6 (n=10)

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Abramson Cancer Center of the University of Pennsylvania Philadelphia, PA

Who Is Running the Clinical Trial?

Abramson Cancer Center of the University of Pennsylvania Lead Sponsor

Abramson Cancer Center at Penn Medicine Lead Sponsor

References